Ovarian tissue remains hormonally active
A research team from the University of Cambridge reported on July 2, 2026 that ovaries in women after menopause continue to secrete hormones and may influence metabolism, challenging the long‑held belief that the organ becomes dormant after egg production ends. The study examined tissue samples from 112 women aged 55 to 70 and measured hormone output over a twelve‑month period.
The investigators found that ovarian stromal cells keep producing estrogen, testosterone, and a peptide called inhibin‑A well beyond the cessation of ovulation. Gene‑expression analysis showed heightened activity in pathways linked to lipid metabolism and immune modulation. Lead author Dr. Maya Patel explained that „the ovary does not simply shut down; it reconfigures its secretory profile to support other physiological systems.” The findings could reshape how clinicians view hormone replacement therapy and the management of age‑related conditions.
Even without follicles, the remaining ovarian tissue retains endocrine capacity. In the study, serum estradiol levels in post‑menopausal participants were on average 30 percent higher than in age‑matched women who had undergone oophorectomy. Testosterone levels also rose modestly, suggesting that the ovary contributes to androgen balance after menopause. Researchers attribute this output to the theca‑like stromal cells, which appear to up‑regulate aromatase enzymes that convert androgens to estrogen. „These cells essentially become the new hormone factory,” said Dr. Patel. The team also detected sustained release of inhibin‑A, a hormone traditionally associated with follicle development, hinting at a broader signaling role.
Could the lingering ovary protect against age‑related disease?
The study explored whether the continued hormone production confers health benefits. Women with intact ovaries displayed slightly better bone mineral density and lower LDL cholesterol compared with those lacking ovaries. Additionally, inflammatory markers such as C‑reactive protein were modestly reduced, implying an anti‑inflammatory effect. While the data are preliminary, the authors propose that the post‑menopausal ovary may act as a buffer against osteoporosis and cardiovascular risk. „If the ovary can still modulate systemic hormones, it might help mitigate some of the metabolic fallout of menopause,” Dr. Patel noted. Future clinical trials will test whether preserving ovarian tissue or mimicking its secretions could become a therapeutic strategy.
The discovery reframes the ovary as a dynamic organ that adapts rather than shuts down after menopause. It opens avenues for personalized hormone therapy that respects the organ’s residual function. As researchers delve deeper, they may uncover novel targets for treating age‑related disorders, turning a once‑overlooked tissue into a key player in women’s health.
Frequently Asked Questions
Do all post‑menopausal women retain ovarian hormone production? Most women keep some ovarian activity, but the degree varies. Factors such as genetics, surgical removal, and overall health influence hormone output.
Should hormone replacement therapy be adjusted based on these findings? Clinicians may need to consider a woman's residual ovarian function when prescribing therapy, but definitive guidelines await further research.
Can the ovary’s new role be harnessed for medical treatments? Researchers are investigating drugs that could amplify the ovary’s protective hormones, potentially offering new options for osteoporosis and heart disease prevention.